GlassScriptPhysician profile
Devin M Bourgeois
NPI 1669913943
$14,263.50
in general payments reported to CMS, 2019-2025
58 companies · $7,152 in 2025
The $7,152 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.78 · 2020: $283 · 2021: $1,554 · 2022: $1,454 · 2023: $1,605 · 2024: $2,129 · 2025: $7,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,674 · Consulting Fee: $3,750 · Travel and Lodging: $331 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,673.93 |
| Consulting Fee | $3,750.00 |
| Travel and Lodging | $331.35 |
| Education | $130.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $4,449.37 | 2020-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $1,675.13 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,125.41 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $704.42 | 2020-2025 | Farxiga, Breztri |
| Pfizer INC. | $666.22 | 2021-2025 | |
| Glaxosmithkline, LLC. | $656.97 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $552.53 | 2021-2025 | Repatha, Repatha, Otezla |
| Esperion Therapeutics, INC. | $384.54 | 2021-2025 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $303.58 | 2024-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.64 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $233.48 | 2021-2025 | |
| Axsome Therapeutics, INC. | $226.60 | 2023-2025 | Auvelity, Sunosi |
| Astellas Pharma US INC | $223.75 | 2021-2025 | Veozah |
| Medtronic, INC. | $172.44 | 2025 | Protege Rx |
| Sumitomo Pharma America, INC. | $153.07 | 2024-2025 | Gemtesa |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Bourgeois listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.